Preliminary Results of a Multicenter, Randomized, Prospective Study Evaluating the Optimal Radiation Dose of Definitive Concurrent Chemoradiation for Inoperable Esophageal Squamous Cell Carcinoma
Y. Xu,X. Zheng,W. Zhu,W. Wang,J. Li,W. Hu,M. A. J,J. Huang,X. Yang,H. He,Z. Liu,T. Zhuang,Z. Sun,J. Zhou,J. Pu,J. Hu,Y. Bao,Z. Liao,M. Chen
DOI: https://doi.org/10.1016/j.ijrobp.2017.06.1080
2017-01-01
Abstract:To determine the optimal radiation dose for definitive concurrent chemoradiation in esophageal squamous cell carcinoma (ESCC) using modern radiation technology. The main included criteria were: pathologically confirmed esophageal squamous cell carcinoma; medically inoperable or patient refusal; clinical stage IIA-IVA (6th edition of the AJCC Staging); age 18-70; KPS ≥70. Radiation had been delivered by intensity-modulated radiation therapy (IMRT). The patients were randomized into high-dose(60Gy) and low-dose group(50Gy). During the thoracic radiotherapy, concurrent weekly chemotherapy with doctaxel 25mg/m2 and cisplatin 25mg/m2 was administrated. After the completion of concurrent chemoradiation, the patients received 2 cycles consolidation chemotherapy with doctaxel 70mg/m2 d1 and cisplatin 25mg/m2d1-3. The primary endpoint was local/regional progression-free survival (LRPFS). ClinicalTrials registration No: NCT01937208. From April 2013 to March 2016, 174 patients were randomized into the high-dose(n=87) and low-dose group(n=87). The median age was 63 years and most of them were male (78.2%). The median tumor length was 5.3cm. The majority of the patients was stage III (66.1%) and located in upper or middle thoracic esophagus (89.6%). There were no significant differences in gender, age, KPS, clinical stage, location, length of tumor between the two groups. The radiotherapy completion rate was 90.8% and 95.4% in the high and low-dose groups respectively. The concurrent weekly chemotherapy completion rates of receiving 5, 4, ≤3 weeks were 64.4% (56/87), 69.0% (60/87); 23.0% (20/87), 19.5% (17/87) and 12.6 % (11/87), 11.5% (10/87), respectively (P=0.807). At a median follow-up of 10.4 months, the disease progression rate was 27.6% (24/87), 31.0% (27/87) in the two groups, respectively (P=0.617), among which local/regional recurrence rate was 19.5% (17/87) and 17.2% (15/87),respectively. The 1, 2-year LRPFS rate was 81.8%, 67.2% and 84.9%, 72.1%, respectively (HR: 1.27, 95% CI: 0.62-2.60,P=0.513). The 1, 2-year PFS rate was 73.4%, 59.4% and 72.0%, 54.0%, respectively (HR: 0.95, 95% CI: 0.55-1.6,P=0.949). A total of 36 patients died, 19 in the high-dose group and 17 in the low-dose group. The 1, 2-year overall survival rate was 87.3%, 56.0% and 87.0%, 74.3%, respectively (HR: 1.2, 95% CI: 0.64-2.38, P=0.524). The treatment toxicity greater than or equal to grade 3 mainly included leukopenia, radiation esophagitis and pneumonitis, the incidence rates were 23.0% (20/87), 28.7% (25/87); 23.0% (20/87), 26.4%(23/87) and 6.9%(6/87),4.5%（4/87）in the two groups (P>0.05). IMRT concurrent with chemotherapy in the treatment of inoperable ESCC is feasible with good treatment completion and short-term curative effect. There was no difference towards LPSFS, PFS, OS and toxicity in both groups. A total of 50Gy might be optimal radiotherapy dose for definitive concurrent chemoradiation in ESCC.The trial is still ongoing.